USE OF [123I]-2-IODO-l-PHENYLALANINE AS A TUMOR IMAGING AGENT IN TWO DOGS WITH SYNOVIAL CELL SARCOMA
Article first published online: 23 AUG 2007
Veterinary Radiology & Ultrasound
Volume 48, Issue 5, pages 471–474, September–October 2007
How to Cite
PEREMANS, K., KERSEMANS, V., LIUTI, T., VANDERMEULEN, E., CORNELISSEN, B., GIELEN, I., DE SPIEGELEER, B., MERTENS, J., BURVENICH, C. and SLEGERS, G. (2007), USE OF [123I]-2-IODO-l-PHENYLALANINE AS A TUMOR IMAGING AGENT IN TWO DOGS WITH SYNOVIAL CELL SARCOMA. Veterinary Radiology & Ultrasound, 48: 471–474. doi: 10.1111/j.1740-8261.2007.00281.x
- Issue published online: 23 AUG 2007
- Article first published online: 23 AUG 2007
- Received September 12, 2006; accepted for publication January 14, 2007.
- gamma camera imaging;
- synovial carcinoma;
- tumor diagnosticum
[123I]-iodo-l-phenylalanine was successfully evaluated for gamma camera imaging in vivo in tumor-bearing athymic mice and in humans with brain tumors. Here, we report the use of this tracer in two dogs with synovial cell sarcoma of the tarsus. [123I]-iodo-l-phenylalanine was quantitatively prepared as a kit formulation using the Cu1+-assisted nucleophilic exchange. Rapid [123I]-2-iodo-l-phenylalanine tumor accumulation was observed with good tumor to background contrast and rapid clearance in these two dogs. This radiopharmaceutical is a promising alternative tumor tracer to overcome the known limitations of 18F-fluorodeoxyglucose and, when labelled with radioiodine-131, has the potential to be used for therapeutic purposes.